ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - vismodegib - קפסולות - vismodegib 150 mg - erivedge® is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - terbutaline sulfate - אבקה לשאיפה - terbutaline sulfate 0.5 mg/dose - terbutaline - terbutaline - for the relief of bronchospasm in patients with reversible onbstructive airway disease, including asthma, chronic bronchitis and emphysema.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - busulfan - תמיסה להזרקה - busulfan 60 mg / 10 ml - busulfan - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 100 mg - bosutinib

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 500 mg - bosutinib

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - busulfan - תמיסה להזרקה - busulfan 60 mg / 10 ml - busulfan

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 400 mg - bosutinib

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - terbutaline sulfate 1.5 mg / 5 ml - elixir - terbutaline - bricalin is indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can bee considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum - based, first- line therapy. gemcitabine in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemothe

ישראל - עברית - Ministry of Health

devries & co. ltd - gemcitabine 200 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap